Patients With Suppressed HIV And M184V/I Viral Mutation Who Switch To Combined B/F/TAF Appear To Maintain Viral Suppression, Analysis Suggests

September 20, 2022

Medscape (9/19, Janeczko, Subscription Publication) says, “People with suppressed HIV and the M184V/I viral mutation who switch medications to combined bictegravir, emtricitabine, and tenofovir alafenamide (B/F/TAF) appear to maintain viral suppression, r...